AndreaBozzo/ceres-open-data-index huggingface dataset:
Table 18. Alcohol Dependence in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs

Table 18. Alcohol Dependence in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs
2018-2020 NSDUH Overview and Summary of Substate Region Estimation Methodology

Substate estimates for these years are no longer available due to methodological concerns with combining 2020 data with data from 2018 and 2019. We apologize for any inconvenience or confusion this may cause.Because of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the three years could be misleading.For more detail on this decision, see the 2018-2020substate data page.
Behavioral Health Barometer: Nebraska, 2014

This is a behavioral health report for the state of Nebraska. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
Hospital Inpatient Discharges (SPARCS De-Identified): Inpatient Quality Indicators (IQI) Area Measures by Patient County: Beginning 2009

The datasets contain hospital discharges counts (numerators, denominators, volume counts), observed, expected and risk-adjusted rates with corresponding 95% confidence intervals for IQIs generated using methodology developed by Agency for Healthcare Research and Quality (AHRQ).
The IQIs are a set of measures that provide a perspective on hospital quality of care using hospital administrative data. These indicators reflect quality of care inside hospitals and include inpatient mortality for certain procedures and medical conditions; utilization of procedures for which there are questions of overuse, underuse, and misuse; and volume of procedures for which there is some evidence that a higher volume of procedures is associated with lower mortality.
All the IQI measures were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data beginning 2009. US Census data files provided by AHRQ were used to derive denominators for county level (area level) IQI measures.

The mortality, volume and utilization measures IQIs are presented by hospital as rates or counts. Area-level utilization measures are presented by county as rates.
Compound 525117: 3-Chloropropyl isohexanoate

Chemical compound data from PubChem database. IUPAC Name: 3-chloropropyl 4-methylpentanoate. Molecular Formula: C9H17ClO2. Molecular Weight: 192.68. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401068-T1: [Translated] IL-9 RECEPTOR ANTAGONISTS

Chemical patent from PubChem database. Patent Number: AT-E401068-T1. Title: Crystalline Forms of Chemical Compounds. Filing Date: 2009-02-06. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: The invention provides novel crystalline forms of chemical compounds, characterized by specific X-ray powder diffraction patterns and thermal properti... IPC Classifications: C07H, A61K, A61P. This patent covers 43 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Patent AT-E401356-T1: [Translated] HOT HOT ADHESIVE COMPOSITION FOR NON-WOVEN FABRICS

Hot-melt adhesive compositions used in non-woven assemblies, comprising: (a) 100 parts by weight of a block copolymer of the formula S-(I/B)-S, wherein S represents a predominantly poly(styrene) block and (I/B) represents a polymer block obtained by at random copolymerization of a mixture of predominantly isoprene and butadiene in a weight ratio in the range of from 70:30 to 30:70, wherein the total block copolymer has a melt flow index measured at 200° C./5 kg in the range of from 0.1 to 12 g/10 min. and has a poly(styrene) content of from 28 to 50 wt % and a coupling efficiency of from 50 to 100%, (b) from 250 to 300 parts by weight of a tackifying resin, (c) from 50 to 150 parts by weight of a plasticizer, and (d) from 0 to 3 parts by weight of auxiliaries, such as stabilizers and/or antioxidants, and disposable articles, comprising at least a non-woven element and assembled by the use of said hot-melt adhesive compositions.
Multi-exon deletions of the

Background
          Mutations in the fibrillin -1 gene (FBN1) cause Marfan syndrome (MFS), an autosomal dominant multi-system connective tissue disorder. The 200 different mutations reported in the 235 kb, 65 exon-containing gene include only one family with a genomic multi-exon deletion.
        
        
          Methods
          We used long-range RT-PCR for mutation detection and long-range genomic PCR and DNA sequencing for identification of deletion breakpoints, allele-specific transcript analyses to determine stability of the mutant RNA, and pulse-chase studies to quantitate fibrillin synthesis and extracellular matrix deposition in cultured fibroblasts. Southern blots of genomic DNA were probed with three overlapping fragments covering the FBN1 coding exons
        
        
          Results
          Two novel multi-exon FBN1 deletions were discovered. Identical nucleotide pentamers were found at or near the intronic breakpoints. In a Case with classic MFS, an in-frame deletion of exons 42 and 43 removed the C-terminal 24 amino acids of the 5th LTBP (8-cysteine) domain and the adjacent 25th calcium-binding EGF-like (6-cysteine) domain. The mutant mRNA was stable, but fibrillin synthesis and matrix deposition were significantly reduced. A Case with severe childhood-onset MFS has a de novo deletion of exons 44–46 that removed three EGF-like domains. Fibrillin protein synthesis was normal, but matrix deposition was strikingly reduced. No genomic rearrangements were detected by Southern analysis of 18 unrelated MFS samples negative for FBN1 mutation screening.
        
        
          Conclusions
          Two novel deletion cases expand knowledge of mutational mechanisms and genotype/phenotype correlations of fibrillinopathies. Deletions or mutations affecting an LTBP domain may result in unstable mutant protein cleavage products that interfere with microfibril assembly.
Compound 527526: 1-(prop-2-yn-1-yl)-1H-pyrrole

Chemical compound data from PubChem database. IUPAC Name: 1-prop-2-ynylpyrrole. Molecular Formula: C7H7N. Molecular Weight: 105.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 CMHS Uniform Reporting System (URS) Output Tables for Utah

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E399882-T1: [Translated] METHOD FOR DETECTING GENETIC MUTATIONS

DNA amplification and hybridization are successively carried out in a reaction system containing primers for the DNA amplification and hybridization probes, followed by detecting the hybrid in the reaction solution by affinity chromatography, wherein at least one of the primers to be used in the DNA amplification is labeled with a first labeling agent so that the amplified DNA will be labeled with the first labeling agent, a hybridization probe is labeled with a second labeling agent and contained in a reaction solution for effecting the DNA amplification, the base sequence of the hybridization probe is designed not to inhibit the DNA amplification, and a hybrid is detected by affinity chromatography with the use of the first and second labeling agents.
Optimality of the genetic code with respect to protein stability and amino-acid frequencies

Background
          The genetic code is known to be efficient in limiting the effect of mistranslation errors. A misread codon often codes for the same amino acid or one with similar biochemical properties, so the structure and function of the coded protein remain relatively unaltered. Previous studies have attempted to address this question quantitatively, by estimating the fraction of randomly generated codes that do better than the genetic code in respect of overall robustness. We extended these results by investigating the role of amino-acid frequencies in the optimality of the genetic code.
        
        
          Results
          We found that taking the amino-acid frequency into account decreases the fraction of random codes that beat the natural code. This effect is particularly pronounced when more refined measures of the amino-acid substitution cost are used than hydrophobicity. To show this, we devised a new cost function by evaluating in silico the change in folding free energy caused by all possible point mutations in a set of protein structures. With this function, which measures protein stability while being unrelated to the code's structure, we estimated that around two random codes in a billion (109) are fitter than the natural code. When alternative codes are restricted to those that interchange biosynthetically related amino acids, the genetic code appears even more optimal.
        
        
          Conclusions
          These results lead us to discuss the role of amino-acid frequencies and other parameters in the genetic code's evolution, in an attempt to propose a tentative picture of primitive life.
Patent AT-E401416-T1: [Translated] METHOD FOR PRODUCING OPTICALLY ACTIVE N-PROTECTED PROPARGYLGLYCINE

A method for producing (S)-N-protected-propargylglycine of the following formula (2), which comprises asymmetrically hydrolyzing an N-protected-propargylglycine of the following formula (1):      nwherein R 1  represents an alkyl group having 1 to 4 carbon atoms, R 2  and R 3  each independently represent a hydrogen atom or a protective group of an amino group, R 2  and R 3  being not simultaneously a hydrogen atom, and a carbon atom appended with a mark * represents an asymmetric carbon atom, nusing an asymmetric hydrolysis enzyme derived from a microorganism selected from Thermomyces genus, Aspergillus genus, Rhizopus genus, Penicillium genus, Pseudomonas genus, Humicola genus, Burkholderia genus, Candida genus and Streptomyces genus, or a cultured substance of a microorganism having an ability of producing this enzyme or a treated substance thereof, nor using an asymmetric hydrolysis enzyme which is ±-amylase derived from a microorganism selected from Bacillus subtilis and Bacillus licheniformis.
Weekly Hospital Respiratory Admission Levels and Rates by Jurisdiction, National Healthcare Safety Network (NHSN)

This dataset provides weekly hospital admission rates and corresponding admission levels for COVID-19, influenza (flu), and respiratory syncytial virus (RSV), aggregated to national and state/territory levels. Each row represents a single jurisdiction (national, state/territory) and reporting week (Sunday through Saturday). 

Data are derived from CDC’s National Healthcare Safety Network (NHSN) Hospital Respiratory Data (HRD), which collect information reported by U.S. acute care and critical access hospitals on laboratory-confirmed COVID-19, influenza, and RSV hospital admissions, and monitors national and local trends in healthcare system stress and capacity. 

Admission rates are calculated per 100,000 population, and admission levels are assigned based on CDC-defined thresholds for each virus. 

New data are appended weekly on Fridays and represent the most recent complete reporting week at the time of publication. Previously published data are not revised or backfilled; all values reflect the data available at the time they were first reported. 

<b>Inclusion Criteria and Metric Calculations</b>

<b>Facility types and status:</b> Acute care and critical access hospitals reporting to NHSN are included in the underlying data used to calculate these metrics. Psychiatric, rehabilitation, and religious non-medical hospital types are excluded. Hospitals are included based on active reporting status in NHSN during the applicable reporting week. 

<b>Admission counts and rates:</b> Weekly admission counts represent the number of new hospital admissions with laboratory-confirmed COVID-19, influenza, or RSV reported by participating hospitals for the reporting week (Sunday–Saturday). Admission rates are calculated by dividing aggregated admissions by the corresponding jurisdictional population and expressed per 100,000 persons. 

<b>Admission levels:</b> Admission levels are categorical indicators (e.g., low, moderate, high, very high) assigned based on CDC-defined thresholds applied to the weekly admission rates for each virus. The thresholds for each pathogen and state can be found online here: <a href="https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting/data-methods.html">https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting/data-methods.html</a>

<b>Reporting considerations:</b> Metrics are based on data submitted by reporting hospitals for a given week and may not represent all hospitals within a jurisdiction. Because previously published data are not revised or backfilled, values reflect the data available at the time of initial reporting.

<b>Source:</b> CDC National Healthcare Safety Network (NHSN).
National Survey of Substance Abuse Treatment Services (N-SSATS-2002)

<p>The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), analyze general treatment services trends, and generate the National Directory of Drug and Alcohol Abuse Treatment Programs and its online equivalent, the Substance Abuse Treatment Facility Locator <a href="http://findtreatment.samhsa.gov">http://findtreatment.samhsa.gov</a>.<br />
Data are collected on topics including facility operation, services offered (assessment, substance abuse therapy and counseling, pharmacotherapies, testing, transitional, ancillary), primary focus (substance abuse, mental health, both, general health, other), hotline operation, Opioid Treatment Programs and medication dispensed, languages in which treatment is provided, type of treatment provided, number of clients (total and under age 18), number of beds, types of payment accepted, sliding fee scale, special programs offered, facility accreditation and licensure/certification, and managed care agreements.This study has 1 Data Set.</p>
Hospital Diversions

<strong>A. SUMMARY</strong>
This dataset includes hospital diversion events declared by San Francisco hospitals.

<strong>B. HOW THE DATASET IS CREATED</strong>
San Francisco hospitals can declare ambulance diversion status, which diverts all ambulance transports away from the hospital of interest except certain specialty calls. This dataset contains number of diversion hours for each hospital. Each record includes the hospital name, the date and time diversion status started, the date and time diversion status ended, and duration of diversion status. 

<strong>C. UPDATE PROCESS</strong>
The data is updated monthly by San Francisco Emergency Medical Services Agency.

<strong>D. HOW TO USE THIS DATASET</strong>
Hospitals are allowed to go on diversion for a maximum of 2 hours before they must re-declare diversion. If 4 or more hospitals go on diversion at the same time, diversion is suspended across all hospitals which means that no hospitals can go on diversion for the next 4 hours. The exception is San Francisco General (SFG) hospital. SFG can declare Trauma Override (functionally identical to hospital diversion) while diversion is suspended since it is San Francisco’s only trauma center. Please refer to the <u><a href="https://data.staff.sf.gov/dataset/Hospital-Suspensions/6x9s-ipug/">Hospital Suspensions dataset</a></u> for more information on diversion suspension.
Evidence for modulation of pericryptal sheath myofibroblasts in rat descending colon by Transforming Growth Factor β and Angiotensin II.

Background
          Absorption of water and Na+ in descending colonic crypts is dependent on the barrier function of the surrounding myofibroblastic pericryptal sheath. Here the effects of high and low Na+ diets and exposure to whole body ionising radiation on the growth and activation of the descending colonic pericryptal myofibroblasts are evaluated. In addition the effect of a post-irradiation treatment with the angiotensin converting enzyme inhibitor Captopril was investigated.
        
        
          Methods
          The levels of Angiotensin II type 1 receptor (AT1), ACE, collagen type IV, transforming growth factor-β type 1 receptor (TGF-βR1), OB cadherin and α-smooth muscle actin in both descending colon and caecum were evaluated, using immunocytochemistry and confocal microscopy, in rats fed on high and low Na+ diets (LS). These parameters were also determined during 3 months post-irradiation with 8Gy from a 60Co source in the presence and absence of the angiotensin converting enzyme inhibitor, Captopril.
        
        
          Results
          Increases in AT1 receptor (135.6% ± 18.3, P < 0.001); ACE (70.1% ± 13.1, P < 0.001); collagen type IV (49.6% ± 15.3, P < 0.001); TGF-β1 receptors (291.0% ± 26.5, P < 0.001); OB-cadherin (26.3% ± 13.8, P < 0.05) and α-smooth muscle actin (82.5% ± 12.4, P < 0.001) were observed in the pericryptal myofibroblasts of the descending colon after LS diet. There are also increases in AT1 receptor and TGF-β1 receptor, smooth muscle actin and collagen type IV after irradiation. Captopril reduced all these effects of irradiation on the pericryptal sheath and also decreased the amount of collagen and smooth muscle actin in control rats (P < 0.001).
        
        
          Conclusions
          These results demonstrate an activation of descending colonic myofibroblasts to trophic stimuli, or irradiation, which can be attenuated by Captopril, indicative of local trophic control by angiotensin II and TGF-β release.
Quality Assurance Reporting Requirements (QARR) Health Disparities 2022

This dataset includes Medicaid Managed Care, Commercial HMO, and Commercial PPO performance data from the Quality Assurance Reporting Requirements (QARR) by member demographic characteristics. QARR is largely based on measures of quality developed and published by the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®). Plans are required to submit quality performance data each year. Demographic information analyzed in this report includes members’ sex, age, race/ethnicity, Medicaid aid category, cash assistance status, behavioral health conditions including serious mental illness (SMI) and substance use disorder (SUD), payer status, and region of residence. Measuring the quality of care, and the ability to measure disparities in care is an important first step to a better understanding of the underlying factors that drive differences in care among certain populations within Medicaid Managed Care, Commercial HMO, and Commercial PPO.

The data is published annually for the Medicaid Managed Care Reports for Quality Performance: Health Care Disparities in New York State http://www.health.ny.gov/health_care/managed_care/reports/
Elk Creek Seismic Waveforms 2011 (Part 17 of 19)

Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.
 
This is download 25 of 48 and corresponds to the time range between October 10, 2011, and November 14, 2011.
Patent AT-E399636-T1: [Translated] METHOD AND DEVICE FOR SHAPING A LONGITUDINALLY CORRUPTED WEB

In a method and device for continuous shaping of a plane web to a lengthwise corrugated web, wherein the web in the shaping area is continuously spatially guided and shaped, in that any imaginary line positioned within the center plane of the web and extending in the transport direction during shaping in the shaping area travels approximately the same travel distance, with increasing shaping only those web lines not positioned at the edge are subjected to a deflection perpendicularly to the plane of the web. The maximum value of the deflection is the greater the farther the web line is removed from the edge of the web, respectively.
Medicare Part D Spending by Drug

The Medicare Part D by Drug dataset presents information on spending for drugs prescribed to Medicare beneficiaries enrolled in Part D by physicians and other healthcare providers. Drugs prescribed in the Medicare Part D program are drugs patients generally administer themselves.

 

The dataset focuses on average spending per dosage unit and change in average spending per dosage unit over time. It also includes spending information for manufacturer(s) of the drugs as well as consumer-friendly information of drug uses and clinical indications.

 

Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments. The Part D spending metrics do not reflect any manufacturers’ rebates or other price concessions as CMS is prohibited from publicly disclosing such information.